With 0.97 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $125.36 whereas the lowest price it dropped to was $119.34. The 52-week range on BNTX shows that it touched its highest point at $131.49 and its lowest point at $76.53 during that stretch. It currently has a 1-year price target of $137.07. BNTX paid its most recent dividend on 1654128000, while the ex-dividend date for that was 1654128000. Beta for the stock currently stands at 0.16.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BNTX was up-trending over the past week, with a rise of 2.81%, but this was up by 14.14% over a month. Three-month performance surged to 21.08% while six-month performance rose 21.31%. The stock gained 20.11% in the past year, while it has gained 15.33% so far this year. A look at the trailing 12-month EPS for BNTX yields -2.15 with Next year EPS estimates of -3.59. For the next quarter, that number is 0.56. This implies an EPS growth rate of -182.97% for this year and -7.01% for next year.
Float and Shares Shorts:
At present, 239.74 million BNTX shares are outstanding with a float of 239.44 million shares on hand for trading. On 2024-11-15, short shares totaled 2.47 million, which was 102.99999 higher than short shares on 1728950400. In addition to Dr. Ugur Sahin M.D. as the firm’s Co-Founder, CEO & Chair of the Management Board, Dr. Ozlem Tureci M.D. serves as its Co-Founder, Chief Medical Officer & Member of Management Board.
Institutional Ownership:
Through their ownership of 0.20633 of BNTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BNTX reported revenue of $1244800000.0 and operating income of $10500000.0. The EBITDA in the recently reported quarter was $211100000.0 and diluted EPS was $0.81.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BNTX since 13 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 2 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BNTX analysts setting a high price target of 172.63286 and a low target of 121.701805, the average target price over the next 12 months is 136.4914. Based on these targets, BNTX could surge 41.83% to reach the target high and fall by -0.01% to reach the target low. Reaching the average price target will result in a growth of 12.14% from current levels.
Analysts have provided yearly estimates in a range of -$1.42001 being high and -$4.35137 being low. For BNTX, this leads to a yearly average estimate of -$3.08914. The surprise factor in the prior quarter was -$2.04. Based on analyst estimates, the high estimate for the next quarter is -$1.23 and the low estimate is -$3.01. The average estimate for the next quarter is thus -$1.95.
